Fulcrum Therapeutics, Inc.

NASDAQ:FULC

Biotechnology

Healthcare
$3.72 +1.71%

+$0.06 today

Market cap
$284.14M
Beta
2.92
P/E (TTM)
-3.6
EPS (TTM)
-$1.00
52W Low $2.83High $15.74

Volume 0.63M

Average 1.78M

FULC Purchases of Investments

Cash used to buy marketable securities and other investments.

Fulcrum Therapeutics, Inc.NASDAQ: FULC

Purchases of Investments · Q1 FY2026 · quarter ended Mar 2026

Purchases of investments growth accelerates

Q1 FY2026 purchases of investments of $155.34M (cash outflow) rose 157.2% year over year, ahead of the +50.2% change in trailing-twelve-month purchases of investments. Sequentially, it rose 494.3% from the prior quarter. Over 3 fiscal years it compounded at +6.0% a year.

Context

  • Purchases of investments grew in size in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +157.2% holds above the trailing-twelve-month pace of +50.2%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$155.34M+494.3% QoQ
Last fiscal yearDec 2025
-$180.22M+0.9% YoY
LTMMar 2026
-$275.16M+50.2% YoY
Purchases of Investments past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+157.2%——
1 year+0.9%——
3-year CAGR+6.0%——
5-year CAGR——
10-year CAGR——

Purchases of Investments history

USD · from the cash flow

Latest · FY2025
(180.22M) USD
Year-over-year change
-0.9%

Purchases of Investments vs competitors

How FULC compares with its peers on the latest reported figures

  • FULC's LTM Mar 2026 purchases of investments of $275.16M is the largest of the 10 companies compared; the peer median is $39.52M.
  • Its year-over-year change of +50.2% is the 3rd highest of 7, against a peer median of +1.5%.
  • Over three fiscal years its annual growth of +6.0% compares with a peer median of -24.4%.
FULC Competitors Peer median
Purchases of Investments for FULC and competitors
Company Period LTM YoY 3-year CAGR% of revenue
FULCFulcrum Therapeutics, Inc.LTM Mar 2026$275.16M +50.2%+6.0%—
NGNENeurogene Inc.LTM Mar 2026$261.83M +16.9%——
CMPXCompass Therapeutics, Inc.LTM Mar 2026$214.54M +201.7%-0.9%—
OMEROmeros CorporationLTM Mar 2026$185.91M -62.9%-24.4%1879.2%
LXRXLexicon Pharmaceuticals, Inc.LTM Mar 2026$182.48M -13.9%+2.3%262.0%
NMRANeumora Therapeutics, Inc. Common StockLTM Mar 2026$39.52M -76.9%-27.6%—
LCTXLineage Cell Therapeutics, Inc.LTM Mar 2026$23.17M +164.5%-34.6%156.8%
OCGNOcugen, Inc.LTM Mar 2026$0 ——0.0%
BCYCBicycle Therapeutics plcLTM Mar 2026$0 ——0.0%
ADCTADC Therapeutics S.A.LTM Mar 2026$0 ——0.0%
Peer median (excluding FULC) $39.52M+1.5%-24.4%78.4%

Competitors are the stored peer set for FULC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(80.85M)(109.87M)(97.34M)(9.73M)(74.88M)
Depreciation & Amortization2.52M2.41M2.17M1.59M1.39M
Deferred Income Tax00000
Stock-Based Compensation11.07M13.35M14.8M14.55M12.47M
Change in Working Capital(11.89M)(3.09M)(4.61M)(4.25M)3.91M
Accounts Receivables(500K)2.5M(308K)(1.56M)2.1M
Inventory1.25M0000
Accounts Payables973K(1.18M)(853K)(1.59M)428K
Other Working Capital(13.61M)(4.42M)(3.45M)(1.1M)1.39M
Other Non-Cash Items673K152K(5.99M)(4.39M)(2.95M)
Operating Cash Flow(78.48M)(97.05M)(90.97M)(2.22M)(60.07M)
Capital Expenditures(1.71M)(1.96M)(508K)(278K)(314K)
Acquisitions (Net)127.96M(14.38M)000
Purchases of Investments(216.23M)(151.15M)(194.89M)(178.59M)(180.22M)
Sales of Investments88.28M165.53M158.71M211.1M211.25M
Other Investing Activities(127.96M)14.38M000
Investing Cash Flow(129.67M)12.41M(36.69M)32.23M30.72M
Debt Repayment(18K)0000
Common Stock Issued182.86M80.8M117.35M2.75M168.67M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities3.67M3.52M777K00
Financing Cash Flow186.51M84.32M118.12M2.75M168.67M
Effect of Forex Changes00000
Net Change in Cash(21.64M)(314K)(9.54M)32.76M139.32M
Free Cash Flow(80.19M)(99.01M)(91.47M)(2.5M)(60.38M)

Fulcrum Therapeutics, Inc.

NASDAQ:FULC

Intrinsic Alpha fair value

Locked

Current Price

$3.72

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.